Fosinopril

This classification denotes an ace inhibitor with the molecular formula C30H46NO7P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R43D2573WO, chemically known as l-proline, 4-cyclohexyl-1-(((2-methyl-1-(1-oxopropoxy)propoxy)(4-phenylbutyl)phosphinyl)acetyl)-, (2alpha,4beta)- but generally known as fosinopril, which bears US NIH Compound Identifier 55891. European Medicines Agency schedules Fosinopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13918MIG. The term FOSINOPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules fosinopril in its Anatomical Therapeutic Chemical (ATC) Classification. FOSINOPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fosinopril under HS 29339990 and SITC 51577. As of Q4 2014, FOSINOPRIL remains the US FDA Preferred Term for this commodity. Fosinopril bears US NLM identifiers UMLS ID C0118168 and NCI Concept Code C65761. SMILES: P(=O)(OC(OC(=O)CC)C(C)C)(CC(=O)N1CC(C2CCCCC2)CC1C(=O)O)CCCCc1ccccc1.